Moledina DG, Parikh CR. Phenotyping of acute kidney injury: beyond serum creatinine. Semin Nephrol. 2018;38(1):3–11.
Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers. 2021;7(1):52.
Donato LJ, Meeusen JW, Lieske JC, Bergmann D, Sparwaßer A, Jaffe AS. Analytical performance of an immunoassay to measure proenkephalin. Clin Biochem. 2018;58:72–7.
Ng LL, Sandhu JK, Narayan H, Quinn PA, Squire IB, Davies JE, Bergmann A, Maisel A, Jones DJ. Proenkephalin and prognosis after acute myocardial infarction. J Am Coll Cardiol. 2014;63(3):280–9.
Beunders R, van Groenendael R, Leijte GP, Kox M, Pickkers P. Proenkephalin compared to conventional methods to assess kidney function in Critically Ill sepsis patients. Shock. 2020;54(3):308–14.
Klein SJ, Brandtner AK, Lehner GF, Ulmer H, Bagshaw SM, Wiedermann CJ, Joannidis M. Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. Intensive Care Med. 2018;44(3):323–36.
Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610–21.
Zhang YL, Qiao SK, Wang RY, Guo XN. NGAL attenuates renal ischemia/reperfusion injury through autophagy activation and apoptosis inhibition in rats. Chem Biol Interact. 2018;289:40–6.
Han M, Li Y, Wen D, Liu M, Ma Y, Cong B. NGAL protects against endotoxin-induced renal tubular cell damage by suppressing apoptosis. BMC Nephrol. 2018;19(1):168.
Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W. A European renal best practice (ERBP) position statement on the kidney disease improving global outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27(12):4263–72.
Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8(9):1482–93.
Caironi P, Latini R, Struck J, Hartmann O, Bergmann A, Bellato V, Ferraris S, Tognoni G, Pesenti A, Gattinoni L, et al. Circulating proenkephalin, acute kidney injury, and its improvement in patients with severe sepsis or shock. Clin Chem. 2018;64(9):1361–9.
Hollinger A, Wittebole X, François B, Pickkers P, Antonelli M, Gayat E, Chousterman BG, Lascarrou JB, Dugernier T, Di Somma S, et al. Proenkephalin A 119–159 (Penkid) is an early biomarker of septic acute kidney injury: the kidney in sepsis and septic shock (Kid-SSS) study. Kidney Int Rep. 2018;3(6):1424–33.
Rosenqvist M, Bronton K, Hartmann O, Bergmann A, Struck J, Melander O. Proenkephalin a 119–159 (penKid) – a novel biomarker for acute kidney injury in sepsis: an observational study. BMC Emerg Med. 2019;19(1):75.
Dépret F, Polina A, Amzallag J, Fayolle-Pivot L, Coutrot M, Chaussard M, Struck J, Hartmann O, Jully M, Fratani A, et al. PenKid measurement at admission is associated with outcome in severely ill burn patients. Burns. 2020;46(6):1302–9.
Marino R, Struck J, Hartmann O, Maisel AS, Rehfeldt M, Magrini L, Melander O, Bergmann A, Di Somma S. Diagnostic and short-term prognostic utility of plasma pro-enkephalin (pro-ENK) for acute kidney injury in patients admitted with sepsis in the emergency department. J Nephrol. 2015;28(6):717–24.
Legrand M, Hollinger A, Vieillard-Baron A, Dépret F, Cariou A, Deye N, Fournier MC, Jaber S, Damoisel C, Lu Q, et al. One-year prognosis of kidney injury at discharge from the ICU: A multicenter observational study. Crit Care Med. 2019;47(12):e953–61.
Kieneker LM, Hartmann O, Bergmann A, de Boer RA, Gansevoort RT, Joosten MM, Struck J, Bakker SJL. Proenkephalin and risk of developing chronic kidney disease: the prevention of renal and vascular end-stage disease study. Biomarkers. 2018;23(5):474–82.
Frigyesi A, Boström L, Lengquist M, Johnsson P, Lundberg OHM, Spångfors M, Annborn M, Cronberg T, Nielsen N, Levin H, et al. Plasma proenkephalin A 119–159 on intensive care unit admission is a predictor of organ failure and 30-day mortality. Intensive care Med Exp. 2021;9(1):36.
Emmens JE, Ter Maaten JM, Damman K, van Veldhuisen DJ, de Boer RA, Struck J, Bergmann A, Sama IE, Streng KW, Anker SD, et al. Proenkephalin, an opioid system surrogate, as a novel comprehensive renal marker in heart failure. Circ Heart Fail. 2019;12(5):e005544.
Siranart N, Laohasurayotin K, Phanthong T, Sowalertrat W, Ariyachaipanich A, Chokesuwattanaskul R. Proenkephalin as a novel prognostic marker in heart failure patients: a systematic review and meta-analysis. Int J Mol Sci. 2023;24(5):4887.
Denning GM, Ackermann LW, Barna TJ, Armstrong JG, Stoll LL, Weintraub NL, Dickson EW. Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissues. Peptides. 2008;29(1):83–92.
Lima C, Gorab DL, Fernandes CR, Macedo E. Role of proenkephalin in the diagnosis of severe and subclinical acute kidney injury during the perioperative period of liver transplantation. Pract Lab Med. 2022;31:e00278.
Gombert A, Barbati M, Hartmann O, Schulte J, Simon T, Simon F. Proenkephalin A 119–159 may predict post-operative acute kidney injury and in hospital mortality following open or endovascular thoraco-abdominal aortic repair. Eur J Vasc Endovasc Surg. 2020;60(3):493–4.
Dépret F, Hollinger A, Cariou A, Deye N, Vieillard-Baron A, Fournier MC, Jaber S, Damoisel C, Lu Q, Monnet X, et al. Incidence and outcome of subclinical acute kidney injury Using penKid in critically Ill patients. Am J Respir Crit Care Med. 2020;202(6):822–9.
Lin LC, Chuan MH, Liu JH, Liao HW, Ng LL, Magnusson M, Jujic A, Pan HC, Wu VC, Forni LG. Proenkephalin as a biomarker correlates with acute kidney injury: a systematic review with meta-analysis and trial sequential analysis. Crit Care. 2023;27(1):481.
Jäntti T, Tarvasmäki T, Harjola VP, Pulkki K, Turkia H, Sabell T, Tolppanen H, Jurkko R, Hongisto M, Kataja A, et al. Predictive value of plasma proenkephalin and neutrophil gelatinase-associated lipocalin in acute kidney injury and mortality in cardiogenic shock. Ann Intensive Care. 2021;11(1):25.
Khorashadi M, Beunders R, Pickkers P, Legrand M. Proenkephalin: a new biomarker for glomerular filtration rate and acute kidney injury. Nephron. 2020;144(12):655–61.
Doukas P, Hartmann O, Arlt B, Jacobs MJ, Greiner A, Frese JP, Gombert A. The role of Proenkephalin A 119–159 in the detection of acute kidney injury after open thoracoabdominal aortic repair. Vasa. 2024;53(1):61–7.
Schulz CA, Christensson A, Ericson U, Almgren P, Hindy G, Nilsson PM, Struck J, Bergmann A, Melander O, Orho-Melander M. High level of fasting plasma proenkephalin-a predicts deterioration of kidney function and incidence of CKD. J Am Soc Nephrol. 2017;28(1):291–303.
von Groote T, Albert F, Meersch M, Koch R, Gerss J, Arlt B, Sadjadi M, Porschen C, Pickkers P, Zarbock A. Evaluation of Proenkephalin A 119–159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury. Crit Care. 2023;27(1):276.
Hill A, Bergmann D, Schulte J, Zayat R, Marx G, Simon TP, Mossanen J, Brücken A, Stoppe C. Proenkephalin A and bioactive adrenomedullin are useful for risk prognostication in cardiac surgery. Front Cardiovasc Med. 2022;9:1017867.
Thorgeirsdóttir B, Levin H, Spångfors M, Annborn M, Cronberg T, Nielsen N, Lybeck A, Friberg H, Frigyesi A. Plasma proenkephalin A 119–159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome. Resuscitation. 2021;163:108–15.
Doehner W, von Haehling S, Suhr J, Ebner N, Schuster A, Nagel E, Melms A, Wurster T, Stellos K, Gawaz M, et al. Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. J Am Coll Cardiol. 2012;60(4):346–54.
Chen XL, Yu BJ, Chen MH. Circulating levels of neuropeptide proenkephalin a predict outcome in patients with aneurysmal subarachnoid hemorrhage. Peptides. 2014;56:111–5.
Ye Z, Liu H, Zhao B, Fu H, Li Y, Chen L. Correlation and diagnostic value of serum Cys-C, RBP4, and NGAL with the condition of patients with traumatic acute kidney injury. Evid Based Complement Alternat Med. 2021;2021:4990941.
Pietrukaniec M, Migacz M, Żak-Gołąb A, Olszanecka-Glinianowicz M, Chudek J, Duława J, Holecki M. Could KIM-1 and NGAL levels predict acute kidney injury after paracentesis? – preliminary study. Ren Fail. 2020;42(1):853–9.
Játiva S, Torrico S, Calle P, Muñoz Á, García M, Larque AB, Poch E, Hotter G. NGAL release from peripheral blood mononuclear cells protects against acute kidney injury and prevents AKI induced fibrosis. Biomed Pharmacother. 2022;153:113415.
Walls AB, Bengaard AK, Iversen E, Nguyen CN, Kallemose T, Juul-Larsen HG, Jawad BN, Hornum M, Andersen O, Eugen-Olsen J, et al. Utility of suPAR and NGAL for AKI risk stratification and early optimization of renal risk medications among older patients in the emergency department. Pharmaceuticals (Basel). 2021;14(9):843.
Wang W, Li Z, Chen Y, Wu H, Zhang S, Chen X. Prediction value of serum NGAL in the diagnosis and prognosis of experimental acute and chronic kidney injuries. Biomolecules. 2020;10(7):981.
Marakala V. Neutrophil gelatinase-associated lipocalin (NGAL) in kidney injury – a systematic review. Clin Chim Acta. 2022;536:135–41.
Larstorp ACK, Salvador CL, Svensvik BA, Klingenberg O, Distante S. Neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C are early biomarkers of acute kidney injury associated with cardiac surgery. Scand J Clin Lab Invest. 2022;82(5):410–8.
Marcello M, Virzì GM, Muciño-Bermejo MJ, Milan Manani S, Giavarina D, Salvador L, Ronco C, Zanella M. Subclinical AKI and clinical outcomes in elderly patients undergoing cardiac surgery: diagnostic utility of ngal versus standard creatinine increase criteria. Cardiorenal Med. 2022;12(3):94–105.
Khawaja S, Jafri L, Siddiqui I, Hashmi M, Ghani F. The utility of neutrophil gelatinase-associated Lipocalin (NGAL) as a marker of acute kidney injury (AKI) in critically ill patients. Biomarker research. 2019;7:4.
Lee CW, Kou HW, Chou HS, Chou HH, Huang SF, Chang CH, Wu CH, Yu MC, Tsai HI. A combination of SOFA score and biomarkers gives a better prediction of septic AKI and in-hospital mortality in critically ill surgical patients: a pilot study. World J Emerg Surg. 2018;13:41.
- The Renal Warrior Project. Join Now
- Source: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03611-0